Objective: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil
Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the …

Objective: To evaluate the long-term safety of OROS methylphenidate in the management of
attention-deficit/hyperactivity disorder (ADHD) in adults. Methods: This multicenter, open …

BACKGROUND: There is increasing recognition of attention-deficit/hyperactivity disorder
(ADHD) in adults and the need to evaluate efficacy and safety of methylphenidate treatment …

BACKGROUND: The objective of this study was to evaluate the safety and efficacy of once-
daily OROS methylphenidate (MPH) in the treatment of adults with DSM-IV attention …

Objectives. Methylphenidate (MPH) is effective for adults with attention-deficit/hyperactivity
disorder (ADHD). This study aimed to evaluate the efficacy and safety of OROS MPH in …

Background Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into
adolescence, little is known about the efficacy and tolerability of stimulant medications in this …

This 8-week, open-label extension of a double-blind study reports on safety data for 171
adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily …

The osmotic release oral system (OROS) methylphenidate formulation is a prolonged-
release medication for the treatment of attention-deficit/hyperactivity disorder (ADHD) in …

OBJECTIVE: Few treatment studies of attention-deficit/hyperactivity disorder (ADHD) extend
beyond a few months. This article reports an interim analysis of a 24-month study evaluating …

Objective: The aim of this study was to evaluate dose–response characteristics in
adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with once-daily …